Updated:
BioIntelliSense
Early Detection Made Simple. The BioButton system delivers scalable continuous monitoring that proactively identifies early signs of patient deterioration.
BioIntelliSense
Early Detection Made Simple. The BioButton system delivers scalable continuous monitoring that proactively identifies early signs of patient deterioration. View our solutions.
General information
Firm type
other
Location
Region
North America
Country
United States
City
Golden
Corporate office
Golden, CO, United States
Sector focus
Frequently asked questions
Who leads BioIntelliSense?
BioIntelliSense does not publicly name its CEO or executive team. The company's website and public filings list no individuals in leadership roles. This contrasts with many health-tech firms that highlight founder or executive backgrounds.
How does BioIntelliSense generate revenue?
BioIntelliSense sells or licenses the BioButton system—hardware, software, and monitoring service—to hospitals, health systems, and post-acute care organizations. The company does not offer direct-to-consumer sales, per its website.
Does BioIntelliSense have venture capital or other institutional investors?
BioIntelliSense has not disclosed any institutional investors, venture capital rounds, or debt financing. Its ownership structure is unknown. This opacity is unusual for a company marketing clinical-trial-level outcomes.
What published evidence supports BioIntelliSense's clinical claims?
BioIntelliSense's website cites several peer-reviewed studies, including research from Houston Methodist published in the Journal of Clinical Medicine (Weller et al., 2024) and a before-and-after study in the British Journal of Anaesthesia (Eddahchouri et al., 2022). The company also references internal analyses from American Health Network and Houston Methodist Hospital.
Is BioIntelliSense structured as a medical device company or a healthcare SaaS firm?
BioIntelliSense appears to operate as a combination medical-device manufacturer (the BioButton wearable) and healthcare software provider (the BioDashboard analytics platform). Its business model includes both hardware sales and recurring software/service revenue, though exact splits are undisclosed.
How does BioIntelliSense's solution differ from standard telemetry or spot-check monitoring?
BioIntelliSense claims that continuous monitoring via the BioButton, compared to intermittent manual vital checks, reduces ICU transfers, rapid response activations, and hospital stays (per studies cited by the company). The system also transitions from in-hospital to home use, a feature not common with traditional telemetry.
Does BioIntelliSense have a philanthropic or nonprofit arm?
BioIntelliSense has not disclosed any philanthropic or nonprofit entity. The for-profit company focuses on commercial sales to healthcare providers. No foundation or charitable structure has been publicly identified.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: